Prerpints.org logo
Preprint
Review

Type II Transmembrane Serine Proteases as Modulators in Adipose Tissue Phenotype and Function

Altmetrics

Downloads

141

Views

68

Comments

0

A peer-reviewed article of this preprint also exists.

This version is not peer-reviewed

Submitted:

24 May 2023

Posted:

25 May 2023

You are already at the latest version

Alerts
Abstract
Adipose tissue is a crucial organ in energy metabolism and thermoregulation. Adipose tissue phenotype is controlled by various signaling mechanisms under pathophysiological conditions. Type II transmembrane serine proteases (TTSPs) are a group of trypsin-like enzymes anchoring on the cell surface. These proteases act in diverse tissues to regulate physiological processes, such as food digestion, salt-water balance, iron metabolism, epithelial integrity, and auditory nerve development. More recently, several members of the TTSP family, namely, hepsin, matriptase-2, and corin, have been shown to play a role in regulating lipid metabolism, adipose tissue phenotype, and thermogenesis, via direct growth factor activation or indirect hormonal mechanisms. In mice, hepsin deficiency increases adipose browning and protects from high-fat diet-induced hyperglycemia, hyperlipidemia, and obesity. Similarly, matriptase-2 deficiency increases fat lipolysis and reduces obesity and hepatic steatosis in high-fat diet-fed mice. In contrast, corin deficiency increases white adipose weights and cell sizes, suppresses adipocyte browning and thermogenic responses, and causes cold intolerance in mice. These findings highlight an important role of TTSPs in modifying cellular phenotype and function in adipose tissue. In this review, we provide a brief description about TTSPs and discuss recent findings regarding the role of hepsin, matriptase-2, and corin in regulating adipose tissue phenotype, energy metabolism, and thermogenic responses.
Keywords: 
Subject: Biology and Life Sciences  -   Endocrinology and Metabolism

1. Introduction

Adipose tissue is an essential organ in energy balance, metabolic homeostasis, and thermogenesis [1]. There are two major types of adipose tissue: white adipose tissue (WAT) and brown adipose tissue (BAT), which serve distinct functions; WAT is primarily for energy storage, whereas BAT is for thermogenesis. The cellular components and activities in adipose tissue are closely regulated by local and systemic signaling mechanisms. Abnormalities in adipose tissue function can lead to metabolic disorders, e.g., obesity and type 2 diabetes, which are major risk factors in leading cardiovascular disease.
Serine proteases are a class of proteolytic enzymes that modify protein structure and function [2]. These proteases act in a wide range of tissues to control physiological processes, including cell growth, embryonic development, and tissue homeostasis. Dysregulated serine protease activities are major contributing factors in cardiovascular disease, neuronal disease, and cancer. In adipose tissue, serine proteases (e.g., adipsin, kallikreins, and proprotein convertases) participate in the activation of growth factors, hormones, adipokines, neuropeptides, and metalloproteinases, which are of metabolic significance. Serine protease inhibitors, also known as serpins (e.g., plasminogen activator inhibitor 1 and vaspin), also play a role in regulating adipose tissue function and are implicated in obesity and metabolic dysfunction.
Type II transmembrane serine proteases (TTSPs) are a group of trypsin-like enzymes important in physiological processes [3,4]. Deficiencies in TTSPs contribute to cardiovascular disease, skin disease, hematological disease, and cancer. In recent years, several TTSPs have been identified as key regulators in adipose tissue phenotype and function. In this review, we provide a brief introduction of TTSPs and discuss roles of hepsin, matriptase-2, and corin in adipose tissue biology and thermogenesis.

2. TTSPs: General Background

2.1. Protein Domains and Post-Translational Modifications

Proteolytic cleavage is one of the most common mechanisms in activating or degrading proteins. The cleavage can also generate protein fragments with new functions, thereby contributing to the functional diversity of the proteome. In the human genome, ~2% genes encode proteolytic enzymes, among which serine proteases are a major class [5]. TTSPs are a family of trypsin-like serine proteases. In humans, the TTSP family has 17 members, all of which have a single-span transmembrane segment near the N-terminus and a trypsin-like serine protease domain at the C-terminus [3]. Based on protein modules between the transmembrane segment and the protease domain, the TTSP family can be divided into four subgroups, i.e., the human airway trypsin-like protease (HAT) subgroup, including HAT, HAT-like (HAT-L) 2-5, TMPRSS11A (transmembrane protease serine 11A), and DESC1 (differentially expressed in squamous cell carcinoma 1), the hepsin subgroup, including hepsin, TMPRSS2-5, enteropeptidase, and MSPL (mosaic serine protease large-form), the matriptase subgroup, including matriptase, matriptase-2-3, and polyserase-1, and the corin subgroup with corin only [3]. Figure 1 shows domain combinations in selected TTSPs representing each of the four subgroups.
TTSPs are synthesized as zymogens, which are activated by proteolytic cleavage at a conserved site before the C-terminal protease domain. To date, distinct molecular and cellular mechanisms have been identified in TTSP zymogen activation. For example, some TTSPs are activated via autocatalysis either intracellularly, e.g., TMPRSS2 [6,7], TMPRSS11A [8], and TMPRSS13 [9], or on the cell surface, e.g., hepsin [10] and matriptase-2 [11,12]. Some TTSPs, e.g., enteropeptidase [13] and corin [14], are activated on the cell surface by other proteolytic enzymes. For matriptase, both autoactivation and prostasin-mediated activation have been reported [15,16,17,18]. Cellular responses to inflammation and oxidative stress also play a regulatory role in TTSP activation [19,20]. The diverse mechanisms in TTSP zymogen activation likely reflect individual protein structures and specific cellular environments, in which the proteases are expressed.
N-glycosylation is a common post-translational modification important in protein folding, intracellular trafficking, and cell surface expression [21]. It has been shown that N-glycans at distinct sites in TTSPs interact with calnexin, an endoplasmic reticulum (ER) chaperone, which facilitates glycoprotein folding, quality control, and ER exiting [22,23]. Abolishing selected N-glycosylation sites in TTSPs prevents the interaction with calnexin, resulting in ER retention of poorly folded proteins and triggering the unfolded protein response and ER stress [22,23,24]. Calreticulin is another ER chaperone in the calnexin-calreticulin cycle of glycoprotein folding [25]. To date, it remains unclear if calreticulin is involved in the folding and intracellular trafficking of TTSPs.
The transmembrane domain in TTSPs tethers the protein on the cell surface. In polarized epithelial cells, TTSPs may be targeted to a specific region of the cell surface. For example, corin is targeted to the apical, but not basolateral, membrane in renal epithelial cells via a Rab11a-dependent sorting mechanism [26]. In non-polarized cardiomyocytes, no selective cell membrane distribution of corin is observed [26,27]. Once on the cell surface, TTSPs may undergo ectodomain shedding, a common process to remove cell surface proteins [28]. Both ectodomain shedding and inhibition by protease inhibitors are important regulatory mechanisms to reduce protease activities. In several TTSPs, including matriptase [29,30,31,32,33], matriptase-2 [12,34], TMPRSS13 [35], corin [36,37], and hepsin [10], autocatalysis and metalloproteinase or cysteine protease-mediated shedding has been reported. Moreover, endocytosis has been identified as another mechanism in regulating matriptase-2 expression and function [34,38]. It remains unclear if TTSPs undergo cell membrane recycling, which are common among many transmembrane proteins.

2.2. Physiological Functions

Based on studies in cells, knockout (KO) mice, and human genetics, physiological functions of many TTSPs have been reported. For example, enteropeptidase is known for trypsinogen activation in food digestion [39]. Matriptase is essential for dermal and intestinal epithelial integrity [40,41,42,43,44]. TMPRSS3 is required for cochlear hair cell survival and normal hearing [45,46,47]. HAT (also known as TMPRSS11D) regulates bronchial epithelial function, including cell proliferation, adhesion, and mucin production [48,49,50,51]. TMPRSS11A is important in skin wound healing [52]. TMPRSS13 and HAT-L4 are critical for skin barrier function [53,54,55]. The function of hepsin [56,57], matriptase-2 [58,59], and corin [60,61,62] in liver function, iron metabolism, and cardiovascular biology, respectively, will be discussed in following sections. In mice, deficiencies in Tmprss2, Tmprss11a, Tmprss11b (also known as HAT-like 5), Tmprss11c (also known as HAT-like 3), HAT, Tmprss11e (also known as DESC1) and Tmprss11g (also known as HAT-like 2) do not cause discernable abnormalities [54,63,64]. More phenotypic studies are needed to elucidate the function of those TTSPs in vivo.
In addition to their roles in normal tissues, TTSPs also act under pathological conditions. In cancers, for example, TTSPs, such as matriptase, hepsin, and TMPRSS13, promote cancer progress by degrading extracellular matrix proteins and activating signaling pathways [65,66,67,68]. In human and mouse airways, multiple TTSPs (e.g., HAT, matriptase, TMPRSS2, TMPRSS4, TMPRSS11A, and TMPRSS13) are expressed on the epithelial surface [69,70]. Proteolytic cleavage of viral particle surface proteins by TTSPs is a key process in host cell entry for influenza A viruses and coronaviruses [69,71,72]. To date, major efforts are ongoing to develop TTSP inhibitors for blocking airway viral infection [73,74]. Hepsin-mediated cleavage STING (stimulator of interferon genes) has also been identified as an important mechanism in inhibiting type I interferon induction in viral infection [75].

3. TTSP Expression in Adipose Tissues

Adipose tissue is an endocrine organ secreting many adipokines and hormones of metabolic importance [76]. In adipose tissue, there are many cell populations, including adipogenic progenitors, adipocytes, fibroblasts, immune cells, and vascular cells. Multiple single-cell and spatial transcriptomic studies, together with proteomic analysis, have identified distinct gene profiles in specific cell types [77,78]. Amazingly, ~70% of protein coding genes in the human genome are expressed in adipose tissue, an indication of dynamic biological activities [79,80]. The gene profiling studies provide important insights into the gene and cellular landscape of human adipose tissue.
Analysis of the Human Protein Atlas database (www.proteinatlas.org) indicates that many genes in adipose tissue encode serine proteases, metalloproteinases, and cysteine proteases. Among them, several TTSP-encoding genes, including HPN (encoding hepsin), ST14 (encoding matriptase), TMPRSS3, TMPRSS5, and TMPRSS11E, are detected. Since all TTSPs contain a cell membrane anchoring domain, the detected TTSPs are expected to function in adipose tissue. To date, the role of matriptase, TMPRSS3, TMPRSS5, and TMPRSS11E in adipose tissue remains to be defined. Conceivably, TTSPs expressed in non-adipose tissues may also alter adipocyte function via indirect mechanisms. In the following sections, we will discuss the role of hepsin, matriptase-2, and corin in regulating adipose tissue function and the underlying mechanisms.

4. Hepsin in Adipose Tissue Differentiation

4.1. Hepsin Protein and Function

Hepsin was discovered in human hepatoma cells [81]. Based on the cDNA sequence, hepsin was predicted to contain an N-terminal transmembrane domain and an extracellular region with a scavenger receptor cysteine-rich (SRCR) domain and a C-terminal trypsin-like protease domain (Figure 1). As shown in biochemical studies, the transmembrane domain is unnecessary for hepsin proteolytic activity. Soluble forms of hepsin are capable of cleaving protein and small peptide substrates [82,83]. The findings are consistent with data in other TTSPs, indicating that the primary function of the transmembrane domain is for cell surface anchoring but not catalytic activity enhancing.
Consistent with its abundant expression in the liver, the primary function of hepsin is to regulate hepatocyte morphology and function. In hepsin KO mice, hepatocytes are larger in size and sinusoidal capillaries are narrower, compared to those in wild-type (WT) mice [57,84]. Hepsin-deficient mice also have reduced levels of triglyceride and glycogen in the liver and low levels of triglyceride, cholesterol, free fatty acids, and albumin in plasma [85,86]. In humans, the HPN locus has been identified as a major determinant of serum albumin levels [87]. These findings indicate an important role of hepsin in regulating lipid, glucose, and protein metabolism in the liver.
The hepatic function of hepsin is mediated, at least in part, by a hepatocyte growth factor (HGF)-dependent mechanism [85]. HGF is a ligand for c-Met, a key tyrosine kinase receptor in cell differentiation [88]. HGF is synthesized as a precursor, i.e., pro-HGF, which is activated on the cell surface by proteolytic cleavage. In cell-based studies, hepsin converted pro-HGF to HGF, leading to c-Met activation [82,83,89]. In livers from hepsin KO mice, pro-HGF processing and phosphorylation of c-Met and its downstream effectors, e.g., Akt, Gsk3, and mTOR, were decreased [57,85]. HGF treatment in hepsin KO mice stimulated c-Met, Akt, Gsk3, and mTOR phosphorylation and glycogen production in the liver [85]. These results indicate that hepsin-mediated pro-HGF processing is critical for c-Met signaling in liver function.
In addition to the liver, hepsin is expressed in the kidney, stomach, thyroid, pancreas, inner ear, and many types of cancers. In renal tubules, hepsin-mediated cleavage is required for uromodulin polymerization in a defense mechanism to prevent bacterial infection in the urinary tract [90,91]. In the inner ear, hepsin is essential for normal cochlear development and auditory nerve function, as indicated by severe hearing loss in hepsin-deficient mice [86,92]. This function is likely mediated by hepsin-mediated pro-HGF activation since a similar hearing loss phenotype was reported in patients with HGF mutations [93]. In breast cancers, hepsin-mediated cleavage of fibronectin in the extracellular matrix has been identified as a key mechanism in transforming growth factor-beta signaling and cancer progression [94].

4.2. Role of Hepsin in Adipose Tissue Browning

As indicated in single-cell sequencing and proteomic analysis, hepsin is expressed in human adipose tissue [79,80]. Hepsin mRNA and protein were also detected in mouse WAT and BAT [85]. Compared to those in WT mice, WAT and BAT weights were lower and adipocyte sizes were smaller in hepsin KO mice, an indication of altered adiposity [85]. In molecular studies, high levels of brown adipocyte markers, such as uncoupling protein 1 (Ucp1) and cell death-inducing DFFA-like effector A (Cidea), were found in hepsin KO BAT and WAT [85]. Additionally, levels of beige adipocyte markers (Cd137 and T-box protein 1) in WAT and mitochondrial gene expression, such as Cox7a1 (encoding cytochrome c oxidase subunit 7A1), Cpt1b and Cpt2 (encoding carnitine palmitoyltransferase 1b and 2, respectively), were increased in hepsin KO BAT and WAT [85]. These results indicate enhanced adipose tissue browning in hepsin KO mice.
Consistently, cultured interscapular BAT and inguinal WAT from hepsin KO mice were more active in glucose uptake [85], an indication of increased metabolism. Indeed, hepsin KO mice exhibited a high metabolic rate, as indicated by increased food and water intakes, core body temperature, heat generation, elevated O2 consumption, CO2 generation, and respiratory exchange ratio [85]. In contrast, no changes in motor activities were observed in hepsin KO mice. Unlike WT mice, hepsin KO mice were protected from developing hyperlipidemia and obesity on high-fat diet. Hepsin deficiency also reduced diabetes and obesity in db/db mice [85]. These data show that hepsin is an important regulator in adipose tissue phenotype and function in mice.
Like in the liver, the hepsin function in adipose tissue is likely mediated by the HGF and c-Met pathway. Both pro-HGF and c-Met are expressed in adipose tissue [85]. In hepsin KO mice, c-Met phosphorylation in adipose tissue was decreased [85]. Moreover, Akt phosphorylation, which suppresses Ucp1 expression in brown adipocytes in a Pgc-1α-mediated mechanism [95], was also reduced in hepsin KO BAT. In culture, differentiated brown adipocytes from hepsin KO mice had high levels of Pgc-1α and Ucp1 expression and O2 consumption [85]. HGF treatment of adipocytes from hepsin KO mice lowered Ucp1 expression in culture [85]. These data point to a cell-autonomous hepsin function in adipose tissue to suppress adipocyte browning via c-Met signaling (Figure 2).

4.3. Regulation of Hepsin Expression in Adipose Tissue

In prostate cancer, HPN is one of the most highly upregulated genes [66]. Similar HPN upregulation occurs in breast, ovarian, liver, and stomach cancers [65]. Oncogenic Ras has been identified as a stimulator in hepsin expression via Raf-MEK-ERK signaling [96]. In normal tissues, the regulation of HPN expression is poorly understood. In WT mice on high-fat diet, no Hpn expression changes were observed in the liver or adipose tissue [85]. In contrast, reduced Hpn mRNA levels were found in the liver and adipose tissue in db/db mice [85]. In WT mice exposed to cold (4ºC), elevated Hpn expression was noticed in the liver and adipose tissue [85]. These findings indicate that genetic and environmental factors may play a role in regulating hepsin function. Further studies will be important to determine if the observed changes are due to direct effects on Hpn expression or secondary effects in response to metabolic imbalance or altered body temperature.

5. Matriptase-2 in Iron Metabolism and Adiposity

5.1. Matriptase-2 in Iron Metabolism

Matriptase-2 is a hepatic TTSP encoded by the TMPRSS6 gene in humans [97]. The protein consists of an N-terminal cytoplasmic segment, a transmembrane domain, and an extracellular region with a SEA (sea urchin sperm protein, enteropeptidase, and agrin) domain, two CUB (complement factor C1s/C1r, urchin embryonic growth factor, and bone morphogenetic protein) domains, three low-density lipoprotein receptor (LDLR) class-A repeats, and a C-terminal trypsin-like protease domain [3,98] (Figure 1). In hepatocytes, matriptase-2 is synthesized as a zymogen, which is activated on the cell surface by autocatalysis [11,12]. The primary function of matriptase-2 is to regulate iron metabolism by suppressing hepcidin, a hormone that downregulates the iron transporter ferroportin [58,97]. In humans and mice, matriptase-2 deficiency results in high levels of serum hepcidin and low levels of ferroportin, which prevents iron efflux in macrophages, intestinal epithelial cells, and hepatocytes, thereby causing iron deficiency anemia [98,99,100,101].
In humans, hepcidin is encoded by the HAMP gene, which is upregulated by bone morphogenetic protein (BMP) signaling [102]. In hepatocytes, the binding of BMP to its cell surface receptors activates downstream signaling, thereby increasing HAMP expression [103]. Hemojuvelin, a co-receptor for BMP in HAMP induction, was identified as a main target of matriptase-2 in hepatocytes [104]. Proteolytic cleavage of hemojuvelin by matriptase-2 reduces BMP signaling and hence hepcidin expression. More recent studies show that hemojuvelin is not the only substrate of matriptase-2. In human hepatoma cells and mouse models, matriptase-2 also cleaves other BMP receptors on the cell surface, including BMP receptor type 1A (also known as ALK3), activin receptor IIA (also known as ActRIIA), hemochromatosis protein, and transferrin receptor-2 that are important in the hepcidin induction pathway [59,105].
The function of most proteases depends on their proteolytic activity. Likewise, the matriptase-2 function in inhibiting BMP signaling was also expected to be mediated by its proteolytic activity. Surprisingly, matriptase-2 binding, via its CUB and protease domains, appears sufficient to sequester and decrease its substrates on the cell surface, resulting in reduced hepcidin expression [105]. These findings show that matriptase-2 may suppress hepcidin expression by targeting multiple proteins in the BMP signaling pathway via proteolytic and non-proteolytic mechanisms [105]. In this regard, matriptase and corin in the TTSP family also exhibit non-proteolytic functions [106,107]. Currently, matriptase-2 inhibitors are being developed to treat iron overload diseases, such as hemochromatosis [108]. Most approaches aim to block matriptase-2 catalytic activity. The finding of the non-proteolytic function in matriptase-2 suggests that targeting matriptase-2 binding to its substrates may be considered as a new approach to increase hepcidin expression as a therapy for iron overload diseases [105].

5.2. Matriptase-2 in Lipolysis and Obesity

Dysregulated iron metabolism and hepcidin expression are associated with obesity, type 2 diabetes, and insulin resistance. For example, hypoferremia, a deficiency of iron in the circulating blood, occurs more frequently in obese individuals [109]. High levels of serum hepcidin and poor iron absorption are also common in obese children and women [110,111]. In obese patients, hepcidin expression is increased in visceral and subcutaneous adipose tissue where levels of inflammatory proteins, e.g., IL-6 and C-reactive protein, are high [112]. In mice, dietary iron overload increases serum hepcidin levels, leading to insulin resistance and decreased visceral adipose tissue [113]. These results suggest a regulatory function of hepcidin in adipose tissue metabolism and/or inflammation.
Given its function in inhibiting hepcidin expression, matriptase-2 may also play a role in regulating metabolism in adipose tissue. In supporting this hypothesis, Tmprss6 KO mice, which had high levels of hepcidin and low levels of plasma iron, were resistant to high-fat diet-induced obesity and hepatic steatosis, as indicated by less total body fat mass, reduced adipocyte sizes and weights in WAT and BAT, and diminished lipid deposits and triglyceride contents in the liver [114]. Additionally, high-fat diet-treated Tmprss6 KO mice exhibited improved glucose tolerance and insulin sensitivity and enhanced fat lipolysis with increased adipose triglyceride lipase expression and phosphorylation/activation of hormone-sensitive lipase in WAT [114].
The mechanism underlying the protective role of matriptase-2 deficiency against obesity and hepatic steatosis is not fully understood. In principle, the observed resistance to obesity in high-fat diet-treated Tmprss6 KO mice could be due to high hepcidin level or low iron level or both. When hypoferremia, but not high hepcidin level, in Tmprss6 mice was corrected by iron injection, the protection against obesity remained [114]. Moreover, iron-treated WT mice, in which hepcidin levels were high, were also resistant to high-fat diet-induced obesity and hepatic steatosis, suggesting that high hepcidin level is primarily responsible for the obesity resistant phenotype [114] (Figure 3). In supporting this idea, injection of an anti-hemojuvelin neutralizing antibody in Tmprss6 KO mice reduced hepcidin levels and eliminated the obesity resistant phenotype [114]. These findings underscore a regulatory role of matriptase-2 and hepcidin in lipid and adipose metabolism. Currently, there is no evidence of matriptase-2 expression in adipose tissue. Additional studies will be important to understand how elevated hepcidin levels increase lipolysis in adipose tissue in Tmprss6 KO mice and if matriptase-2 deficiency also protects against obesity in humans.

6. Corin in Adipose Tissue Phenotype and Thermogenesis

6.1. Corin in Pro-ANP Processing

Corin was discovered in the heart [115]. The primary function of corin is to activate atrial natriuretic peptide (ANP) [116], a pleiotropic hormone produced in the heart and, at low levels, in non-cardiac tissues. In the heart, ANP serves as a key component in a hormonal mechanism to control blood volume and pressure by relaxing vessels and increasing renal sodium and water excretion [117]. Moreover, ANP regulates cardiac morphology, function, and aging [118,119]. In the pregnant uterus, ANP promotes decidualization and spiral artery remodeling in an auto/paracrine mechanism critical for fetal growth [120,121]. Impaired ANP expression and/or function have been implicated in major cardiovascular diseases, including atrial fibrillation, hypertension, cardiac hypertrophy, heart failure, and preeclampsia [122].
Like many peptide hormones, ANP is derived from its precursor, i.e., pro-ANP, via proteolytic cleavage. The cleavage is carried out by corin on the cell surface [123]. Like other TTSPs, corin has a single-pass transmembrane domain near the N-terminus. In the extracellular region, there are two frizzled domains, eight LDLR class-A repeats, an SRCR domain and a C-terminal protease domain (Figure 1). Corin-mediated pro-ANP cleavage occurs not only in the heart, but also in non-cardiac tissues, including the kidney, skin, and uterus [120,124,125]. Disruption of the Corin gene prevents pro-ANP processing in mice, causing salt-sensitive hypertension that is also observed in ANP KO mice [126,127]. In humans, deleterious CORIN variants are associated with impaired pro-ANP processing and hypertensive diseases [128,129,130,131,132].

6.2. Role of ANP in Lipid Metabolism in Adipose Tissue

In addition to its function in salt-water balance and blood pressure, ANP enhances cellular activity and lipid metabolism in adipose tissue. In cultured adipocytes, ANP treatment increases lipolysis by stimulating phosphorylation of the hormone-sensitive lipase and perilipin A, a lipid droplet coating protein that recruits lipases in adipocytes [133]. This ANP function is mediated by increasing intracellular cGMP generation and subsequent activation of the cGMP-dependent protein kinase I (cGKI). Inhibition of cGKI, but not the cAMP-dependent protein kinase (PKA), reduced ANP-mediated lipolysis in adipocytes [133]. Consistently, intravenous ANP infusion in humans increased lipid hydrolysis and oxidation in subcutaneous abdominal adipose tissue [134]. Similarly, enhancing natriuretic peptide signaling by deleting the Nprc gene (encoding natriuretic peptide clearance receptor) in mouse adipose tissue decreased adipocyte size, stimulated lipid metabolism, and prevented diet-induced obesity and insulin resistance [135]. Conversely, in mouse and rat models of obesity, cardiac ANP expression is suppressed [136,137]. It appears that the ANP-mediated lipid-mobilizing function is independent of sympathetic nervous system activation [138]. In addition to adipose tissue, ANP also promotes lipid oxidation in skeletal muscles [139]. These data indicate that ANP is an important hormone that connects the heart and adipose tissue in controlling lipid and energy metabolism.

6.3. Role of ANP in Adipose Tissue Browning and Thermogenesis

BAT is essential for non-shivering thermogenesis, a survival response in cold environments [1]. ANP has been shown to promote the browning thermogenic program in human and mouse adipocytes [140]. In ANP-treated adipocytes, levels of UCP1 and mitochondrial gene expression are markedly increased. This function is mediated by a signaling pathway involving protein kinase G (PKG) and p38 mitogen-activated protein kinase (MAPK) [140,141], resulting in the activation of the transcriptional co-activator PGC-1α, a key regulator of mitochondrial biogenesis and thermogenesis in BAT [95]. In mice, ANP administration enhanced adipose tissue browning and thermogenetic activities and reduced insulin resistance induced by high-fat diet [142]. Likewise, treatment of B-type natriuretic peptide, another natriuretic peptide with similar activities to those of ANP, elevated Ucp1 expression in adipocytes in culture and in mice [140,143]. Consistently, ANP deficiency reduces BAT activity, resulting in cold intolerance in mice [144]. Based on comparative biology studies, the natriuretic peptides were originated in primitive fish species to regulate electrolyte homeostasis [145,146]. Apparently, the function of ANP has expanded in endothermic animals to provide an additional adaptive advantage in new environments where salt intakes and temperatures fluctuate widely.

6.4. Role of ANP in Adipose Tissue Inflammation

In obese individuals, chronic inflammation in adipose tissue contributes to insulin resistance, metabolic dysfunction, and risks of cardiovascular disease [147,148]. Inhibition of inflammation has been considered as a therapeutic target in obesity. ANP is anti-inflammatory [149,150]. In cultured human subcutaneous adipose tissue, ANP treatment inhibited the expression and secretion of multiple adipokines (e.g., leptin and retinol-binding protein-4) in adipocytes and cytokines (e.g., TNFα, IL-6, and monocyte chemoattractant protein-1) in macrophages [151], which are implicated in inflammation and metabolic dysfunction. In mice, inhibition of natriuretic peptide removal by disrupting the Nprc gene decreased inflammation and oxidative stress in adipose tissue, particularly when the mice were in a pro-atherosclerotic ApoE-/- background [152]. Human genetic studies have also linked NPRC alleles and risks of abdominal adiposity [153]. These findings underscore a role of ANP-dependent mechanism in preventing chronic inflammation in adipose tissue, which contribute to insulin resistance and type 2 diabetes.

6.5. Impaired Adipose Tissue Browning and Thermogenesis in Corin KO Mice

Corin is essential for ANP activation [126]. Given the role of ANP in adipose tissue, it is anticipated that corin deficiency may alter adipose tissue phenotype. Indeed, a recent study reported that Corin KO mice had impaired adipocyte browning, as observed in ANP KO mice [154]. Particularly, Corin KO mice had an increased fat mass vs. body weight ratio, larger adipocyte sizes in WAT, and reduced Ucp1 and Cidea expression in BAT. Moreover, decreased p38 Mapk phosphorylation, Pgc-1α level, and mitochondrial gene expression were also observed in BAT from Corin KO mice [154]. In culture, ANP treatment increased Ucp1 expression in BAT-derived adipocytes from Corin KO mice [154]. These data indicate that corin deficiency prevents ANP generation, thereby impairing the cGKI/hormone-sensitive lipase-mediated lipolysis and the p38 Mapk-Pgc-1α-Ucp1 signaling pathway in adipose tissue browning in mice (Figure 4).
Consistent with impaired adipocyte browning, Corin KO mice had a phenotype of poor thermogenic response and cold intolerance [154]. When tested at regular room temperature (~22°C), Corin KO mice exhibited no major metabolic abnormalities, as measured by motor activity, heat generation, O2 consumption, CO2 production, water and food intakes, and core body temperature. Upon cold exposure (4°C), core body temperature deceased more rapidly in Corin KO mice than in WT mice, indicating that Corin KO mice are prone to developing hypothermia [154]. In WT mice exposed to cold, blood glucose level and Ucp1 expression were increased in WAT and BAT, as part of the thermogenic response. In contrast, such a response was markedly diminished in cold-exposed Corin KO mice [154]. These results indicate that corin-mediated ANP activation is critical for non-shivering thermogenesis in response to cold exposure in mice. In humans, CORIN and NPPA (encoding prepro-ANP) expression was found in visceral and subcutaneous adipose tissue from obese individuals [155], suggesting a potential auto- or paracrine mechanism of corin and ANP in adipose tissue. In C57BL/6J WT mice, however, Corin and Nppa mRNAs were not detected by RT-PCR in inguinal WAT and interscapular BAT [154]. Further studies are required to understand if the corin and ANP function in adipose tissue is mediated by endocrine and/or auto/paracrine mechanism(s) in humans and mice.
It is worth noting that sweating is a key thermoregulatory mechanism to reduce core body temperature in hot environments or during hard labor or exercises. Among all mammals, humans have the most abundant eccrine sweat glands present nearly the entire skin surface [156]. This anatomical characteristic offers an advantage for humans to live in hot and dry territories [157,158]. As reported recently, both corin and ANP are expressed in human and mouse skin eccrine sweat glands [125]. In mice, corin deficiency reduced sodium and sweat excretion in paw skin [125]. Apparently, the corin function, via ANP activation, serves as an anti-aldosterone mechanism to promote sodium and water excretion in the sweating duct [125]. These findings highlight the role of corin in thermoregulation via two independent mechanisms: enhancing adipocyte browning and non-shivering thermogenesis under cold conditions and promoting sweat excretion in skin eccrine glands under hot conditions. More studies will be important to determine if and how CORIN variants may alter adipocyte function, thermoregulation, and adaptive fitness in humans.

7. Conclusions and Perspectives

It has been more than 20 years since TTSPs were cloned and recognized as a distinct group of proteolytic enzymes [159]. The importance of TTSPs in many physiological processes, such as sodium homeostasis, iron metabolism, epithelial integrity, vascular remodeling, and auditory nerve development, is well documented. Defects in TTSPs have been shown to cause cardiovascular, hematological, intestinal, skin, and hearing disorders. Upregulated TTSP expression also contributes to cancer development and progression. In respiratory viral infection, epithelial TTSPs in human airways play a major role in activating viral particle proteins, thereby enhancing viral infectivity.
Adipose tissue is essential in energy metabolism and thermoregulation. Dysregulated adipose function is a major factor in the pathogenesis of metabolic and cardiovascular diseases. Recent studies in mouse models have shown that members of the TTSP family, namely hepsin, matriptase-2, and corin, play an important role in regulating adipose phenotype and thermogenesis via direct signaling or indirect hormonal mechanisms. More studies are expected to verify these findings and to examine if additional underling mechanisms are involved. It will also be important to determine if hepsin, matriptase-2, and corin play similar roles in human adipose tissue and participate in metabolic diseases, such as obesity, dyslipidemia, and type 2 diabetes.
As revealed by single-cell and spatial transcriptomic studies, there are additional TTSPs (e.g., matriptase, TMPRSS3, TMPRSS5, and TMPRSS11E) expressed in human adipose tissue. Further studies are required to determine if these TTSPs act in adipose tissue to regulate cellular components and activities. Findings from such studies shall help to understand the role of TTSPs in adipose tissue function, metabolic homeostasis, and thermogenesis, which are of great biological significance.

Author Contributions

Conceptualization, Q.W.; writing—original draft preparation, Q.W.; writing—review, discussion, and editing, Q.W., S.L., X.Z., and N.D.; funding acquisition, N.D.; All authors have read and agreed to the publication version of the manuscript.

Funding

This work was supported, in part, by grants from the National Natural Science Foundation of China (81873840 and 32171112 to N.D.) and the Priority Academic Program Development of Jiangsu Higher Education Institutes (to Soochow University).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We thank former and current lab members for their contributions.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Sakers, A.; De Siqueira, M.K.; Seale, P.; Villanueva, C.J. Adipose-tissue plasticity in health and disease. Cell 2022, 185, 419-446. [CrossRef]
  2. Perona, J.J.; Craik, C.S. Structural basis of substrate specificity in the serine proteases. Protein Sci 1995, 4, 337-360. [CrossRef]
  3. Bugge, T.H.; Antalis, T.M.; Wu, Q. Type II transmembrane serine proteases. J Biol Chem 2009, 284, 23177-23181. [CrossRef]
  4. Wu, Q. Type II transmembrane serine proteases. Curr Top Dev Biol 2003, 54, 167-206. [CrossRef]
  5. Overall, C.M.; Blobel, C.P. In search of partners: linking extracellular proteases to substrates. Nat Rev Mol Cell Biol 2007, 8, 245-257. [CrossRef]
  6. Zhang, Y.; Sun, S.; Du, C.; Hu, K.; Zhang, C.; Liu, M.; Wu, Q.; Dong, N. Transmembrane serine protease TMPRSS2 implicated in SARS-CoV-2 infection is autoactivated intracellularly and requires N-glycosylation for regulation. J Biol Chem 2022, 298, 102643. [CrossRef]
  7. Afar, D.E.; Vivanco, I.; Hubert, R.S.; Kuo, J.; Chen, E.; Saffran, D.C.; Raitano, A.B.; Jakobovits, A. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res 2001, 61, 1686-1692.
  8. Zhang, C.; Zhang, Y.; Zhang, S.; Wang, Z.; Sun, S.; Liu, M.; Chen, Y.; Dong, N.; Wu, Q. Intracellular autoactivation of TMPRSS11A, an airway epithelial transmembrane serine protease. J Biol Chem 2020, 295, 12686-12696. [CrossRef]
  9. Murray, A.S.; Varela, F.A.; Hyland, T.E.; Schoenbeck, A.J.; White, J.M.; Tanabe, L.M.; Todi, S.V.; List, K. Phosphorylation of the type II transmembrane serine protease, TMPRSS13, in hepatocyte growth factor activator inhibitor-1 and -2-mediated cell-surface localization. J Biol Chem 2017, 292, 14867-14884. [CrossRef]
  10. Wang, L.; Zhang, C.; Sun, S.; Chen, Y.; Hu, Y.; Wang, H.; Liu, M.; Dong, N.; Wu, Q. Autoactivation and calpain-1-mediated shedding of hepsin in human hepatoma cells. Biochem J 2019, 476, 2355-2369. [CrossRef]
  11. Stirnberg, M.; Maurer, E.; Horstmeyer, A.; Kolp, S.; Frank, S.; Bald, T.; Arenz, K.; Janzer, A.; Prager, K.; Wunderlich, P.; et al. Proteolytic processing of the serine protease matriptase-2: identification of the cleavage sites required for its autocatalytic release from the cell surface. Biochem J 2010, 430, 87-95. [CrossRef]
  12. Jiang, J.; Yang, J.; Feng, P.; Zuo, B.; Dong, N.; Wu, Q.; He, Y. N-glycosylation is required for matriptase-2 autoactivation and ectodomain shedding. J Biol Chem 2014, 289, 19500-19507. [CrossRef]
  13. Lu, D.; Yuan, X.; Zheng, X.; Sadler, J.E. Bovine proenteropeptidase is activated by trypsin, and the specificity of enteropeptidase depends on the heavy chain. J Biol Chem 1997, 272, 31293-31300. [CrossRef]
  14. Chen, S.; Cao, P.; Dong, N.; Peng, J.; Zhang, C.; Wang, H.; Zhou, T.; Yang, J.; Zhang, Y.; Martelli, E.E.; et al. PCSK6-mediated corin activation is essential for normal blood pressure. Nat Med 2015, 21, 1048-1053. [CrossRef]
  15. Wang, J.K.; Teng, I.J.; Lo, T.J.; Moore, S.; Yeo, Y.H.; Teng, Y.C.; Kaul, M.; Chen, C.C.; Zuo, A.H.; Chou, F.P.; et al. Matriptase autoactivation is tightly regulated by the cellular chemical environments. PLoS One 2014, 9, e93899. [CrossRef]
  16. Jia, B.; Thompson, H.A.; Barndt, R.B.; Chiu, Y.L.; Lee, M.J.; Lee, S.C.; Wang, J.K.; Tang, H.J.; Lin, C.Y.; Johnson, M.D. Mild acidity likely accelerates the physiological matriptase autoactivation process: a comparative study between spontaneous and acid-induced matriptase zymogen activation. Hum Cell 2020, 33, 1068-1080. [CrossRef]
  17. Friis, S.; Uzzun Sales, K.; Godiksen, S.; Peters, D.E.; Lin, C.Y.; Vogel, L.K.; Bugge, T.H. A matriptase-prostasin reciprocal zymogen activation complex with unique features: prostasin as a non-enzymatic co-factor for matriptase activation. J Biol Chem 2013, 288, 19028-19039. [CrossRef]
  18. Szabo, R.; Lantsman, T.; Peters, D.E.; Bugge, T.H. Delineation of proteolytic and non-proteolytic functions of the membrane-anchored serine protease prostasin. Development 2016, 143, 2818-2828. [CrossRef]
  19. Chen, C.Y.; Chen, C.J.; Lai, C.H.; Wu, B.Y.; Lee, S.P.; Johnson, M.D.; Lin, C.Y.; Wang, J.K. Increased matriptase zymogen activation by UV irradiation protects keratinocyte from cell death. J Dermatol Sci 2016, 83, 34-44. [CrossRef]
  20. Wilkinson, D.J.; Desilets, A.; Lin, H.; Charlton, S.; Del Carmen Arques, M.; Falconer, A.; Bullock, C.; Hsu, Y.C.; Birchall, K.; Hawkins, A.; et al. The serine proteinase hepsin is an activator of pro-matrix metalloproteinases: molecular mechanisms and implications for extracellular matrix turnover. Sci Rep 2017, 7, 16693. [CrossRef]
  21. Reily, C.; Stewart, T.J.; Renfrow, M.B.; Novak, J. Glycosylation in health and disease. Nat Rev Nephrol 2019, 15, 346-366. [CrossRef]
  22. Wang, H.; Li, S.; Wang, J.; Chen, S.; Sun, X.L.; Wu, Q. N-glycosylation in the protease domain of trypsin-like serine proteases mediates calnexin-assisted protein folding. eLife 2018, 7, e35672. [CrossRef]
  23. Sun, S.; Hu, K.; Wang, L.; Liu, M.; Zhang, Y.; Dong, N.; Wu, Q. Spatial position is a key determinant of N-glycan functionality of the scavenger receptor cysteine-rich domain of human hepsin. Febs j 2023, 10.1111/febs.16757. [CrossRef]
  24. Sun, S.; Wang, L.; Zhang, S.; Zhang, C.; Chen, Y.; Wu, Q.; Dong, N. N-glycan in the scavenger receptor cysteine-rich domain of hepsin promotes intracellular trafficking and cell surface expression. Int J Biol Macromol 2020, 161, 818-827. [CrossRef]
  25. Kozlov, G.; Gehring, K. Calnexin cycle - structural features of the ER chaperone system. Febs j 2020, 287, 4322-4340. [CrossRef]
  26. Zhang, C.; Chen, Y.; Sun, S.; Zhang, Y.; Wang, L.; Luo, Z.; Liu, M.; Dong, L.; Dong, N.; Wu, Q. A conserved LDL-receptor motif regulates corin and CD320 membrane targeting in polarized renal epithelial cells. eLife 2020, 9, e56059. [CrossRef]
  27. Gladysheva, I.P.; Robinson, B.R.; Houng, A.K.; Kováts, T.; King, S.M. Corin is co-expressed with pro-ANP and localized on the cardiomyocyte surface in both zymogen and catalytically active forms. J Mol Cell Cardiol 2008, 44, 131-142. [CrossRef]
  28. Lichtenthaler, S.F.; Lemberg, M.K.; Fluhrer, R. Proteolytic ectodomain shedding of membrane proteins in mammals-hardware, concepts, and recent developments. Embo j 2018, 37. [CrossRef]
  29. Tseng, C.C.; Jia, B.; Barndt, R.; Gu, Y.; Chen, C.Y.; Tseng, I.C.; Su, S.F.; Wang, J.K.; Johnson, M.D.; Lin, C.Y. Matriptase shedding is closely coupled with matriptase zymogen activation and requires de novo proteolytic cleavage likely involving its own activity. PLoS One 2017, 12, e0183507. [CrossRef]
  30. Yoon, J.; Cho, Y.; Kim, K.Y.; Yoon, M.J.; Lee, H.S.; Jeon, S.D.; Kim, C.; Kim, M.G. A JUN N-terminal kinase inhibitor induces ectodomain shedding of the cancer-associated membrane protease Prss14/epithin via protein kinase CβII. J Biol Chem 2020, 295, 7168-7177. [CrossRef]
  31. Najy, A.J.; Dyson, G.; Jena, B.P.; Lin, C.Y.; Kim, H.R. Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis. Am J Physiol Cell Physiol 2016, 310, C293-304. [CrossRef]
  32. Friis, S.; Sales, K.U.; Schafer, J.M.; Vogel, L.K.; Kataoka, H.; Bugge, T.H. The protease inhibitor HAI-2, but not HAI-1, regulates matriptase activation and shedding through prostasin. J Biol Chem 2014, 289, 22319-22332. [CrossRef]
  33. Larsen, B.R.; Steffensen, S.D.; Nielsen, N.V.; Friis, S.; Godiksen, S.; Bornholdt, J.; Soendergaard, C.; Nonboe, A.W.; Andersen, M.N.; Poulsen, S.S.; et al. Hepatocyte growth factor activator inhibitor-2 prevents shedding of matriptase. Exp Cell Res 2013, 319, 918-929. [CrossRef]
  34. Zhao, N.; Nizzi, C.P.; Anderson, S.A.; Wang, J.; Ueno, A.; Tsukamoto, H.; Eisenstein, R.S.; Enns, C.A.; Zhang, A.S. Low intracellular iron increases the stability of matriptase-2. J Biol Chem 2015, 290, 4432-4446. [CrossRef]
  35. Martin, C.E.; Murray, A.S.; Mackinder, J.R.; Sala-Hamrick, K.E.; Flynn, M.G.; Lundgren, J.G.; Varela, F.A.; List, K. TMPRSS13 zymogen activation, surface localization, and shedding is regulated by proteolytic cleavage within the non-catalytic stem region. Biol Chem 2022, 403, 969-982. [CrossRef]
  36. Jiang, J.; Wu, S.; Wang, W.; Chen, S.; Peng, J.; Zhang, X.; Wu, Q. Ectodomain shedding and autocleavage of the cardiac membrane protease corin. J Biol Chem 2011, 286, 10066-10072. [CrossRef]
  37. Wang, H.; Zhou, T.; Peng, J.; Xu, P.; Dong, N.; Chen, S.; Wu, Q. Distinct roles of N-glycosylation at different sites of corin in cell membrane targeting and ectodomain shedding. J Biol Chem 2015, 290, 1654-1663. [CrossRef]
  38. Béliveau, F.; Brulé, C.; Désilets, A.; Zimmerman, B.; Laporte, S.A.; Lavoie, C.L.; Leduc, R. Essential role of endocytosis of the type II transmembrane serine protease TMPRSS6 in regulating its functionality. J Biol Chem 2011, 286, 29035-29043. [CrossRef]
  39. Zheng, X.L.; Kitamoto, Y.; Sadler, J.E. Enteropeptidase, a type II transmembrane serine protease. Front Biosci (Elite Ed) 2009, 1, 242-249. [CrossRef]
  40. List, K.; Kosa, P.; Szabo, R.; Bey, A.L.; Wang, C.B.; Molinolo, A.; Bugge, T.H. Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. Am J Pathol 2009, 175, 1453-1463. [CrossRef]
  41. Buzza, M.S.; Netzel-Arnett, S.; Shea-Donohue, T.; Zhao, A.; Lin, C.Y.; List, K.; Szabo, R.; Fasano, A.; Bugge, T.H.; Antalis, T.M. Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine. Proc Natl Acad Sci U S A 2010, 107, 4200-4205. [CrossRef]
  42. Szabo, R.; Bugge, T.H. Membrane-anchored serine proteases as regulators of epithelial function. Biochem Soc Trans 2020, 48, 517-528. [CrossRef]
  43. Wu, C.J.; Feng, X.; Lu, M.; Morimura, S.; Udey, M.C. Matriptase-mediated cleavage of EpCAM destabilizes claudins and dysregulates intestinal epithelial homeostasis. J Clin Invest 2017, 127, 623-634. [CrossRef]
  44. Szabo, R.; Callies, L.K.; Bugge, T.H. Matriptase drives early-onset intestinal failure in a mouse model of congenital tufting enteropathy. Development 2019, 146. [CrossRef]
  45. Fasquelle, L.; Scott, H.S.; Lenoir, M.; Wang, J.; Rebillard, G.; Gaboyard, S.; Venteo, S.; François, F.; Mausset-Bonnefont, A.L.; Antonarakis, S.E.; et al. Tmprss3, a transmembrane serine protease deficient in human DFNB8/10 deafness, is critical for cochlear hair cell survival at the onset of hearing. J Biol Chem 2011, 286, 17383-17397. [CrossRef]
  46. Molina, L.; Fasquelle, L.; Nouvian, R.; Salvetat, N.; Scott, H.S.; Guipponi, M.; Molina, F.; Puel, J.L.; Delprat, B. Tmprss3 loss of function impairs cochlear inner hair cell Kcnma1 channel membrane expression. Hum Mol Genet 2013, 22, 1289-1299. [CrossRef]
  47. Battelino, S.; Klancar, G.; Kovac, J.; Battelino, T.; Trebusak Podkrajsek, K. TMPRSS3 mutations in autosomal recessive nonsyndromic hearing loss. Eur Arch Otorhinolaryngol 2016, 273, 1151-1154. [CrossRef]
  48. Menou, A.; Duitman, J.; Flajolet, P.; Sallenave, J.M.; Mailleux, A.A.; Crestani, B. Human airway trypsin-like protease, a serine protease involved in respiratory diseases. Am J Physiol Lung Cell Mol Physiol 2017, 312, L657-l668. [CrossRef]
  49. Matsushima, R.; Takahashi, A.; Nakaya, Y.; Maezawa, H.; Miki, M.; Nakamura, Y.; Ohgushi, F.; Yasuoka, S. Human airway trypsin-like protease stimulates human bronchial fibroblast proliferation in a protease-activated receptor-2-dependent pathway. Am J Physiol Lung Cell Mol Physiol 2006, 290, L385-395. [CrossRef]
  50. Miki, M.; Nakamura, Y.; Takahashi, A.; Nakaya, Y.; Eguchi, H.; Masegi, T.; Yoneda, K.; Yasuoka, S.; Sone, S. Effect of human airway trypsin-like protease on intracellular free Ca2+ concentration in human bronchial epithelial cells. J Med Invest 2003, 50, 95-107.
  51. Beaufort, N.; Leduc, D.; Eguchi, H.; Mengele, K.; Hellmann, D.; Masegi, T.; Kamimura, T.; Yasuoka, S.; Fend, F.; Chignard, M.; et al. The human airway trypsin-like protease modulates the urokinase receptor (uPAR, CD87) structure and functions. Am J Physiol Lung Cell Mol Physiol 2007, 292, L1263-1272. [CrossRef]
  52. Fernandez, C.; Burgos, A.; Morales, D.; Rosales-Rojas, R.; Canelo, J.; Vergara-Jaque, A.; Vieira, G.V.; da Silva, R.A.A.; Sales, K.U.; Conboy, M.J.; et al. TMPRSS11a is a novel age-altered, tissue specific regulator of migration and wound healing. Faseb j 2021, 35, e21597. [CrossRef]
  53. Zhang, Z.; Hu, Y.; Yan, R.; Dong, L.; Jiang, Y.; Zhou, Z.; Liu, M.; Zhou, T.; Dong, N.; Wu, Q. The Transmembrane Serine Protease HAT-like 4 Is Important for Epidermal Barrier Function to Prevent Body Fluid Loss. Sci Rep 2017, 7, 45262. [CrossRef]
  54. Callies, L.K.; Tadeo, D.; Simper, J.; Bugge, T.H.; Szabo, R. Iterative, multiplexed CRISPR-mediated gene editing for functional analysis of complex protease gene clusters. J Biol Chem 2019, 294, 15987-15996. [CrossRef]
  55. Madsen, D.H.; Szabo, R.; Molinolo, A.A.; Bugge, T.H. TMPRSS13 deficiency impairs stratum corneum formation and epidermal barrier acquisition. Biochem J 2014, 461, 487-495. [CrossRef]
  56. Li, S.; Wang, L.; Sun, S.; Wu, Q. Hepsin: a multifunctional transmembrane serine protease in pathobiology. FEBS J 2021, 288, 5252-5264. [CrossRef]
  57. Hsu, Y.C.; Huang, H.P.; Yu, I.S.; Su, K.Y.; Lin, S.R.; Lin, W.C.; Wu, H.L.; Shi, G.Y.; Tao, M.H.; Kao, C.H.; et al. Serine protease hepsin regulates hepatocyte size and hemodynamic retention of tumor cells by hepatocyte growth factor signaling in mice. Hepatology 2012, 56, 1913-1923. [CrossRef]
  58. Stirnberg, M.; Gütschow, M. Matriptase-2, a regulatory protease of iron homeostasis: possible substrates, cleavage sites and inhibitors. Curr Pharm Des 2013, 19, 1052-1061. [CrossRef]
  59. Wahedi, M.; Wortham, A.M.; Kleven, M.D.; Zhao, N.; Jue, S.; Enns, C.A.; Zhang, A.S. Matriptase-2 suppresses hepcidin expression by cleaving multiple components of the hepcidin induction pathway. J Biol Chem 2017, 292, 18354-18371. [CrossRef]
  60. Zhou, Y.; Wu, Q. Corin in natriuretic peptide processing and hypertension. Curr Hypertens Rep 2014, 16, 415. [CrossRef]
  61. Zhang, X.; Gu, X.; Zhang, Y.; Dong, N.; Wu, Q. Corin: A Key Mediator in Sodium Homeostasis, Vascular Remodeling, and Heart Failure. Biology (Basel) 2022, 11. [CrossRef]
  62. Sullivan, R.D.; Houng, A.K.; Gladysheva, I.P.; Fan, T.M.; Tripathi, R.; Reed, G.L.; Wang, D. Corin Overexpression Reduces Myocardial Infarct Size and Modulates Cardiomyocyte Apoptotic Cell Death. Int J Mol Sci 2020, 21. [CrossRef]
  63. Kim, T.S.; Heinlein, C.; Hackman, R.C.; Nelson, P.S. Phenotypic analysis of mice lacking the Tmprss2-encoded protease. Mol Cell Biol 2006, 26, 965-975. [CrossRef]
  64. Sales, K.U.; Hobson, J.P.; Wagenaar-Miller, R.; Szabo, R.; Rasmussen, A.L.; Bey, A.; Shah, M.F.; Molinolo, A.A.; Bugge, T.H. Expression and genetic loss of function analysis of the HAT/DESC cluster proteases TMPRSS11A and HAT. PLoS One 2011, 6, e23261. [CrossRef]
  65. Martin, C.E.; List, K. Cell surface-anchored serine proteases in cancer progression and metastasis. Cancer Metastasis Rev 2019, 38, 357-387. [CrossRef]
  66. Wu, Q.; Parry, G. Hepsin and prostate cancer. Front Biosci 2007, 12, 5052-5059. [CrossRef]
  67. Murray, A.S.; Hyland, T.E.; Sala-Hamrick, K.E.; Mackinder, J.R.; Martin, C.E.; Tanabe, L.M.; Varela, F.A.; List, K. The cell-surface anchored serine protease TMPRSS13 promotes breast cancer progression and resistance to chemotherapy. Oncogene 2020, 39, 6421-6436. [CrossRef]
  68. Mukai, S.; Yamasaki, K.; Fujii, M.; Nagai, T.; Terada, N.; Kataoka, H.; Kamoto, T. Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers. Int J Mol Sci 2020, 21. [CrossRef]
  69. Fuentes-Prior, P. Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection. J Biol Chem 2021, 296, 100135. [CrossRef]
  70. Harbig, A.; Mernberger, M.; Bittel, L.; Pleschka, S.; Schughart, K.; Steinmetzer, T.; Stiewe, T.; Nist, A.; Böttcher-Friebertshäuser, E. Transcriptome profiling and protease inhibition experiments identify proteases that activate H3N2 influenza A and influenza B viruses in murine airways. J Biol Chem 2020, 295, 11388-11407. [CrossRef]
  71. Murza, A.; Dion, S.P.; Boudreault, P.L.; Désilets, A.; Leduc, R.; Marsault, É. Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract - A review of patent literature. Expert Opin Ther Pat 2020, 30, 807-824. [CrossRef]
  72. Forni, D.; Sironi, M.; Cagliani, R. Evolutionary history of type II transmembrane serine proteases involved in viral priming. Hum Genet 2022, 141, 1705-1722. [CrossRef]
  73. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.H.; Nitsche, A.; et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181, 271-280.e278. [CrossRef]
  74. Shapira, T.; Monreal, I.A.; Dion, S.P.; Buchholz, D.W.; Imbiakha, B.; Olmstead, A.D.; Jager, M.; Désilets, A.; Gao, G.; Martins, M.; et al. A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Nature 2022, 605, 340-348. [CrossRef]
  75. Hsin, F.; Hsu, Y.C.; Tsai, Y.F.; Lin, S.W.; Liu, H.M. The transmembrane serine protease hepsin suppresses type I interferon induction by cleaving STING. Sci Signal 2021, 14. [CrossRef]
  76. Scheja, L.; Heeren, J. The endocrine function of adipose tissues in health and cardiometabolic disease. Nat Rev Endocrinol 2019, 15, 507-524. [CrossRef]
  77. Massier, L.; Jalkanen, J.; Elmastas, M.; Zhong, J.; Wang, T.; Nono Nankam, P.A.; Frendo-Cumbo, S.; Bäckdahl, J.; Subramanian, N.; Sekine, T.; et al. An integrated single cell and spatial transcriptomic map of human white adipose tissue. Nat Commun 2023, 14, 1438. [CrossRef]
  78. Hildreth, A.D.; Ma, F.; Wong, Y.Y.; Sun, R.; Pellegrini, M.; O'Sullivan, T.E. Single-cell sequencing of human white adipose tissue identifies new cell states in health and obesity. Nat Immunol 2021, 22, 639-653. [CrossRef]
  79. Uhlén, M.; Fagerberg, L.; Hallström, B.M.; Lindskog, C.; Oksvold, P.; Mardinoglu, A.; Sivertsson, Å.; Kampf, C.; Sjöstedt, E.; Asplund, A.; et al. Proteomics. Tissue-based map of the human proteome. Science 2015, 347, 1260419. [CrossRef]
  80. Karlsson, M.; Zhang, C.; Méar, L.; Zhong, W.; Digre, A.; Katona, B.; Sjöstedt, E.; Butler, L.; Odeberg, J.; Dusart, P.; et al. A single-cell type transcriptomics map of human tissues. Sci Adv 2021, 7. [CrossRef]
  81. Leytus, S.P.; Loeb, K.R.; Hagen, F.S.; Kurachi, K.; Davie, E.W. A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. Biochemistry 1988, 27, 1067-1074. [CrossRef]
  82. Xuan, J.A.; Schneider, D.; Toy, P.; Lin, R.; Newton, A.; Zhu, Y.; Finster, S.; Vogel, D.; Mintzer, B.; Dinter, H.; et al. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res 2006, 66, 3611-3619. [CrossRef]
  83. Herter, S.; Piper, D.E.; Aaron, W.; Gabriele, T.; Cutler, G.; Cao, P.; Bhatt, A.S.; Choe, Y.; Craik, C.S.; Walker, N.; et al. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J 2005, 390, 125-136. [CrossRef]
  84. Hsu, Y.C.; Yu, I.S.; Tsai, Y.F.; Wu, Y.M.; Chen, Y.T.; Sheu, J.C.; Lin, S.W. A Preconditioning Strategy to Augment Retention and Engraftment Rate of Donor Cells During Hepatocyte Transplantation. Transplantation 2021, 105, 785-795. [CrossRef]
  85. Li, S.; Peng, J.; Wang, H.; Zhang, W.; Brown, J.M.; Zhou, Y.; Wu, Q. Hepsin enhances liver metabolism and inhibits adipocyte browning in mice. Proc Natl Acad Sci U S A 2020, 117, 12359-12367. [CrossRef]
  86. Aljakna, A.; Choi, S.; Savage, H.; Hageman Blair, R.; Gu, T.; Svenson, K.L.; Churchill, G.A.; Hibbs, M.; Korstanje, R. Pla2g12b and Hpn are genes identified by mouse ENU mutagenesis that affect HDL cholesterol. PLoS One 2012, 7, e43139. [CrossRef]
  87. Franceschini, N.; van Rooij, F.J.; Prins, B.P.; Feitosa, M.F.; Karakas, M.; Eckfeldt, J.H.; Folsom, A.R.; Kopp, J.; Vaez, A.; Andrews, J.S.; et al. Discovery and fine mapping of serum protein loci through transethnic meta-analysis. Am J Hum Genet 2012, 91, 744-753. [CrossRef]
  88. Koch, J.P.; Aebersold, D.M.; Zimmer, Y.; Medová, M. MET targeting: time for a rematch. Oncogene 2020, 39, 2845-2862. [CrossRef]
  89. Tervonen, T.A.; Belitškin, D.; Pant, S.M.; Englund, J.I.; Marques, E.; Ala-Hongisto, H.; Nevalaita, L.; Sihto, H.; Heikkilä, P.; Leidenius, M.; et al. Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion. Oncogene 2016, 35, 1832-1846. [CrossRef]
  90. Brunati, M.; Perucca, S.; Han, L.; Cattaneo, A.; Consolato, F.; Andolfo, A.; Schaeffer, C.; Olinger, E.; Peng, J.; Santambrogio, S.; et al. The serine protease hepsin mediates urinary secretion and polymerisation of Zona Pellucida domain protein uromodulin. Elife 2015, 4, e08887. [CrossRef]
  91. Olinger, E.; Lake, J.; Sheehan, S.; Schiano, G.; Takata, T.; Tokonami, N.; Debaix, H.; Consolato, F.; Rampoldi, L.; Korstanje, R.; et al. Hepsin-mediated Processing of Uromodulin is Crucial for Salt-sensitivity and Thick Ascending Limb Homeostasis. Sci Rep 2019, 9, 12287. [CrossRef]
  92. Guipponi, M.; Tan, J.; Cannon, P.Z.; Donley, L.; Crewther, P.; Clarke, M.; Wu, Q.; Shepherd, R.K.; Scott, H.S. Mice deficient for the type II transmembrane serine protease, TMPRSS1/hepsin, exhibit profound hearing loss. Am J Pathol 2007, 171, 608-616. [CrossRef]
  93. Naz, S. Molecular genetic landscape of hereditary hearing loss in Pakistan. Hum Genet 2022, 141, 633-648. [CrossRef]
  94. Belitškin, D.; Pant, S.M.; Munne, P.; Suleymanova, I.; Belitškina, K.; Hongisto, H.A.; Englund, J.; Raatikainen, T.; Klezovitch, O.; Vasioukhin, V.; et al. Hepsin regulates TGFβ signaling via fibronectin proteolysis. EMBO Rep 2021, 22, e52532. [CrossRef]
  95. Puigserver, P.; Spiegelman, B.M. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003, 24, 78-90. [CrossRef]
  96. Tervonen, T.A.; Pant, S.M.; Belitškin, D.; Englund, J.I.; Närhi, K.; Haglund, C.; Kovanen, P.E.; Verschuren, E.W.; Klefström, J. Oncogenic Ras Disrupts Epithelial Integrity by Activating the Transmembrane Serine Protease Hepsin. Cancer Res 2021, 81, 1513-1527. [CrossRef]
  97. Ramsay, A.J.; Hooper, J.D.; Folgueras, A.R.; Velasco, G.; López-Otín, C. Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis. Haematologica 2009, 94, 840-849. [CrossRef]
  98. Ramsay, A.J.; Reid, J.C.; Velasco, G.; Quigley, J.P.; Hooper, J.D. The type II transmembrane serine protease matriptase-2--identification, structural features, enzymology, expression pattern and potential roles. Front Biosci 2008, 13, 569-579. [CrossRef]
  99. Finberg, K.E.; Heeney, M.M.; Campagna, D.R.; Aydinok, Y.; Pearson, H.A.; Hartman, K.R.; Mayo, M.M.; Samuel, S.M.; Strouse, J.J.; Markianos, K.; et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008, 40, 569-571. [CrossRef]
  100. Du, X.; She, E.; Gelbart, T.; Truksa, J.; Lee, P.; Xia, Y.; Khovananth, K.; Mudd, S.; Mann, N.; Moresco, E.M.; et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science 2008, 320, 1088-1092. [CrossRef]
  101. Cui, Y.; Wu, Q.; Zhou, Y. Iron-refractory iron deficiency anemia: new molecular mechanisms. Kidney Int 2009, 76, 1137-1141. [CrossRef]
  102. Babitt, J.L.; Huang, F.W.; Wrighting, D.M.; Xia, Y.; Sidis, Y.; Samad, T.A.; Campagna, J.A.; Chung, R.T.; Schneyer, A.L.; Woolf, C.J.; et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006, 38, 531-539. [CrossRef]
  103. Muckenthaler, M.U.; Rivella, S.; Hentze, M.W.; Galy, B. A Red Carpet for Iron Metabolism. Cell 2017, 168, 344-361. [CrossRef]
  104. Silvestri, L.; Pagani, A.; Nai, A.; De Domenico, I.; Kaplan, J.; Camaschella, C. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008, 8, 502-511. [CrossRef]
  105. Enns, C.A.; Jue, S.; Zhang, A.S. The ectodomain of matriptase-2 plays an important nonproteolytic role in suppressing hepcidin expression in mice. Blood 2020, 136, 989-1001. [CrossRef]
  106. Friis, S.; Tadeo, D.; Le-Gall, S.M.; Jürgensen, H.J.; Sales, K.U.; Camerer, E.; Bugge, T.H. Matriptase zymogen supports epithelial development, homeostasis and regeneration. BMC Biol 2017, 15, 46. [CrossRef]
  107. Tripathi, R.; Sullivan, R.D.; Fan, T.M.; Houng, A.K.; Mehta, R.M.; Reed, G.L.; Gladysheva, I.P. Cardiac-Specific Overexpression of Catalytically Inactive Corin Reduces Edema, Contractile Dysfunction, and Death in Mice with Dilated Cardiomyopathy. Int J Mol Sci 2019, 21, 203. [CrossRef]
  108. Beckmann, A.M.; Maurer, E.; Lülsdorff, V.; Wilms, A.; Furtmann, N.; Bajorath, J.; Gütschow, M.; Stirnberg, M. En Route to New Therapeutic Options for Iron Overload Diseases: Matriptase-2 as a Target for Kunitz-Type Inhibitors. Chembiochem 2016, 17, 595-604. [CrossRef]
  109. McClung, J.P.; Karl, J.P. Iron deficiency and obesity: the contribution of inflammation and diminished iron absorption. Nutr Rev 2009, 67, 100-104. [CrossRef]
  110. del Giudice, E.M.; Santoro, N.; Amato, A.; Brienza, C.; Calabrò, P.; Wiegerinck, E.T.; Cirillo, G.; Tartaglione, N.; Grandone, A.; Swinkels, D.W.; et al. Hepcidin in obese children as a potential mediator of the association between obesity and iron deficiency. J Clin Endocrinol Metab 2009, 94, 5102-5107. [CrossRef]
  111. Stoffel, N.U.; El-Mallah, C.; Herter-Aeberli, I.; Bissani, N.; Wehbe, N.; Obeid, O.; Zimmermann, M.B. The effect of central obesity on inflammation, hepcidin, and iron metabolism in young women. Int J Obes (Lond) 2020, 44, 1291-1300. [CrossRef]
  112. Bekri, S.; Gual, P.; Anty, R.; Luciani, N.; Dahman, M.; Ramesh, B.; Iannelli, A.; Staccini-Myx, A.; Casanova, D.; Ben Amor, I.; et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006, 131, 788-796. [CrossRef]
  113. Dongiovanni, P.; Ruscica, M.; Rametta, R.; Recalcati, S.; Steffani, L.; Gatti, S.; Girelli, D.; Cairo, G.; Magni, P.; Fargion, S.; et al. Dietary iron overload induces visceral adipose tissue insulin resistance. Am J Pathol 2013, 182, 2254-2263. [CrossRef]
  114. Folgueras, A.R.; Freitas-Rodríguez, S.; Ramsay, A.J.; Garabaya, C.; Rodríguez, F.; Velasco, G.; López-Otín, C. Matriptase-2 deficiency protects from obesity by modulating iron homeostasis. Nat Commun 2018, 9, 1350. [CrossRef]
  115. Yan, W.; Sheng, N.; Seto, M.; Morser, J.; Wu, Q. Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart. J Biol Chem 1999, 274, 14926-14935. [CrossRef]
  116. Yan, W.; Wu, F.; Morser, J.; Wu, Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A 2000, 97, 8525-8529. [CrossRef]
  117. Goetze, J.P.; Bruneau, B.G.; Ramos, H.R.; Ogawa, T.; de Bold, M.K.; de Bold, A.J. Cardiac natriuretic peptides. Nat Rev Cardiol 2020, 17, 698-717. [CrossRef]
  118. Kuhn, M. Cardiac actions of atrial natriuretic peptide: new visions of an old friend. Circ Res 2015, 116, 1278-1280. [CrossRef]
  119. Zhan, W.; Chen, L.; Liu, H.; Long, C.; Liu, J.; Ding, S.; Wu, Q.; Chen, S. Pcsk6 Deficiency Promotes Cardiomyocyte Senescence by Modulating Ddit3-Mediated ER Stress. Genes (Basel) 2022, 13. [CrossRef]
  120. Cui, Y.; Wang, W.; Dong, N.; Lou, J.; Srinivasan, D.K.; Cheng, W.; Huang, X.; Liu, M.; Fang, C.; Peng, J.; et al. Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy. Nature 2012, 484, 246-250. [CrossRef]
  121. Zhang, W.; Li, S.; Lou, J.; Li, H.; Liu, M.; Dong, N.; Wu, Q. Atrial natriuretic peptide promotes uterine decidualization and a TRAIL-dependent mechanism in spiral artery remodeling. J Clin Invest 2021, 131, e151053. [CrossRef]
  122. Song, W.; Wang, H.; Wu, Q. Atrial natriuretic peptide in cardiovascular biology and disease (NPPA). Gene 2015, 569, 1-6. [CrossRef]
  123. Dong, N.; Niu, Y.; Chen, Y.; Sun, S.; Wu, Q. Function and regulation of corin in physiology and disease. Biochem Soc Trans 2020, 48, 1905-1916. [CrossRef]
  124. Zhou, T.; Zhang, S.; Du, C.; Wang, K.; Gu, X.; Sun, S.; Zhang, X.; Niu, Y.; Wang, C.; Liu, M.; et al. Renal Corin Is Essential for Normal Blood Pressure and Sodium Homeostasis. Int J Mol Sci 2022, 23, 11251. [CrossRef]
  125. He, M.; Zhou, T.; Niu, Y.; Feng, W.; Gu, X.; Xu, W.; Zhang, S.; Wang, Z.; Zhang, Y.; Wang, C.; et al. The protease corin regulates electrolyte homeostasis in eccrine sweat glands. PLoS Biol 2021, 19, e3001090. [CrossRef]
  126. Chan, J.C.; Knudson, O.; Wu, F.; Morser, J.; Dole, W.P.; Wu, Q. Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci U S A 2005, 102, 785-790. [CrossRef]
  127. Wang, W.; Shen, J.; Cui, Y.; Jiang, J.; Chen, S.; Peng, J.; Wu, Q. Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice. Kidney Int 2012, 82, 26-33. [CrossRef]
  128. Dong, N.; Fang, C.; Jiang, Y.; Zhou, T.; Liu, M.; Zhou, J.; Shen, J.; Fukuda, K.; Qin, J.; Wu, Q. Corin mutation R539C from hypertensive patients impairs zymogen activation and generates an inactive alternative ectodomain fragment. J Biol Chem 2013, 288, 7867-7874. [CrossRef]
  129. Zhang, Y.; Zhou, T.; Niu, Y.; He, M.; Wang, C.; Liu, M.; Yang, J.; Zhou, J.; Fukuda, K.; Qin, J.; et al. Identification and functional analysis of CORIN variants in hypertensive patients. Hum Mutat 2017, 38, 1700-1710. [CrossRef]
  130. Rame, J.E.; Tam, S.W.; McNamara, D.; Worcel, M.; Sabolinski, M.L.; Wu, A.H.; Dries, D.L. Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the Genetic Risk Assessment in Heart Failure substudy. Circ Heart Fail 2009, 2, 541-548. [CrossRef]
  131. Dong, N.; Zhou, T.; Zhang, Y.; Liu, M.; Li, H.; Huang, X.; Liu, Z.; Wu, Y.; Fukuda, K.; Qin, J.; et al. Corin mutations K317E and S472G from preeclamptic patients alter zymogen activation and cell surface targeting. J Biol Chem 2014, 289, 17909-17916. [CrossRef]
  132. Zhao, Y.; Yuan, X.; Zhong, Y.; Zhang, Y.; Zhang, S.; Li, S.; Zheng, W.; Liu, J.; Xia, Y.; Yang, Y.; et al. Single-Nucleotide Polymorphisms in the 3' Untranslated Region of CORIN Associated With Cardiovascular Diseases in a Chinese Han Population: A Case-Control Study. Front Cardiovasc Med 2021, 8, 625072. [CrossRef]
  133. Sengenes, C.; Bouloumie, A.; Hauner, H.; Berlan, M.; Busse, R.; Lafontan, M.; Galitzky, J. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem 2003, 278, 48617-48626. [CrossRef]
  134. Birkenfeld, A.L.; Budziarek, P.; Boschmann, M.; Moro, C.; Adams, F.; Franke, G.; Berlan, M.; Marques, M.A.; Sweep, F.C.; Luft, F.C.; et al. Atrial natriuretic peptide induces postprandial lipid oxidation in humans. Diabetes 2008, 57, 3199-3204. [CrossRef]
  135. Wu, W.; Shi, F.; Liu, D.; Ceddia, R.P.; Gaffin, R.; Wei, W.; Fang, H.; Lewandowski, E.D.; Collins, S. Enhancing natriuretic peptide signaling in adipose tissue, but not in muscle, protects against diet-induced obesity and insulin resistance. Sci Signal 2017, 10, eaam6870. [CrossRef]
  136. Cabiati, M.; Raucci, S.; Liistro, T.; Belcastro, E.; Prescimone, T.; Caselli, C.; Matteucci, M.; Iozzo, P.; Mattii, L.; Giannessi, D.; et al. Impact of obesity on the expression profile of natriuretic peptide system in a rat experimental model. PLoS One 2013, 8, e72959. [CrossRef]
  137. Bartels, E.D.; Nielsen, J.M.; Bisgaard, L.S.; Goetze, J.P.; Nielsen, L.B. Decreased expression of natriuretic peptides associated with lipid accumulation in cardiac ventricle of obese mice. Endocrinology 2010, 151, 5218-5225. [CrossRef]
  138. Galitzky, J.; Sengenès, C.; Thalamas, C.; Marques, M.A.; Senard, J.M.; Lafontan, M.; Berlan, M. The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men. J Lipid Res 2001, 42, 536-544.
  139. Engeli, S.; Birkenfeld, A.L.; Badin, P.M.; Bourlier, V.; Louche, K.; Viguerie, N.; Thalamas, C.; Montastier, E.; Larrouy, D.; Harant, I.; et al. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Invest 2012, 122, 4675-4679. [CrossRef]
  140. Bordicchia, M.; Liu, D.; Amri, E.Z.; Ailhaud, G.; Dessì-Fulgheri, P.; Zhang, C.; Takahashi, N.; Sarzani, R.; Collins, S. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest 2012, 122, 1022-1036. [CrossRef]
  141. Coué, M.; Moro, C. Natriuretic peptide control of energy balance and glucose homeostasis. Biochimie 2016, 124, 84-91. [CrossRef]
  142. Kimura, H.; Nagoshi, T.; Oi, Y.; Yoshii, A.; Tanaka, Y.; Takahashi, H.; Kashiwagi, Y.; Tanaka, T.D.; Yoshimura, M. Treatment with atrial natriuretic peptide induces adipose tissue browning and exerts thermogenic actions in vivo. Sci Rep 2021, 11, 17466. [CrossRef]
  143. Liu, D.; Ceddia, R.P.; Collins, S. Cardiac natriuretic peptides promote adipose 'browning' through mTOR complex-1. Mol Metab 2018, 9, 192-198. [CrossRef]
  144. Carper, D.; Coué, M.; Nascimento, E.B.M.; Barquissau, V.; Lagarde, D.; Pestourie, C.; Laurens, C.; Petit, J.V.; Soty, M.; Monbrun, L.; et al. Atrial Natriuretic Peptide Orchestrates a Coordinated Physiological Response to Fuel Non-shivering Thermogenesis. Cell Rep 2020, 32, 108075. [CrossRef]
  145. Inoue, K.; Sakamoto, T.; Yuge, S.; Iwatani, H.; Yamagami, S.; Tsutsumi, M.; Hori, H.; Cerra, M.C.; Tota, B.; Suzuki, N.; et al. Structural and functional evolution of three cardiac natriuretic peptides. Mol Biol Evol 2005, 22, 2428-2434. [CrossRef]
  146. Loretz, C.A.; Pollina, C. Natriuretic peptides in fish physiology. Comp Biochem Physiol A Mol Integr Physiol 2000, 125, 169-187. [CrossRef]
  147. Chait, A.; den Hartigh, L.J. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front Cardiovasc Med 2020, 7, 22. [CrossRef]
  148. Zatterale, F.; Longo, M.; Naderi, J.; Raciti, G.A.; Desiderio, A.; Miele, C.; Beguinot, F. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front Physiol 2019, 10, 1607. [CrossRef]
  149. Staedtke, V.; Bai, R.Y.; Kim, K.; Darvas, M.; Davila, M.L.; Riggins, G.J.; Rothman, P.B.; Papadopoulos, N.; Kinzler, K.W.; Vogelstein, B.; et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 2018, 564, 273-277. [CrossRef]
  150. Mezzasoma, L.; Antognelli, C.; Talesa, V.N. Atrial natriuretic peptide down-regulates LPS/ATP-mediated IL-1β release by inhibiting NF-kB, NLRP3 inflammasome and caspase-1 activation in THP-1 cells. Immunol Res 2016, 64, 303-312. [CrossRef]
  151. Moro, C.; Klimcakova, E.; Lolmède, K.; Berlan, M.; Lafontan, M.; Stich, V.; Bouloumié, A.; Galitzky, J.; Arner, P.; Langin, D. Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia 2007, 50, 1038-1047. [CrossRef]
  152. Cheng, C.; Xue, F.; Sui, W.; Meng, L.; Xie, L.; Zhang, C.; Yang, J.; Zhang, Y. Deletion of natriuretic peptide receptor C alleviates adipose tissue inflammation in hypercholesterolemic Apolipoprotein E knockout mice. J Cell Mol Med 2021, 25, 9837-9850. [CrossRef]
  153. Sarzani, R.; Strazzullo, P.; Salvi, F.; Iacone, R.; Pietrucci, F.; Siani, A.; Barba, G.; Gerardi, M.C.; Dessì-Fulgheri, P.; Rappelli, A. Natriuretic peptide clearance receptor alleles and susceptibility to abdominal adiposity. Obes Res 2004, 12, 351-356. [CrossRef]
  154. Zhang, X.; Li, W.; Zhou, T.; Liu, M.; Wu, Q.; Dong, N. Corin Deficiency Alters Adipose Tissue Phenotype and Impairs Thermogenesis in Mice. Biology (Basel) 2022, 11, 1101. [CrossRef]
  155. Garruti, G.; Giusti, V.; Nussberger, J.; Darimont, C.; Verdumo, C.; Amstutz, C.; Puglisi, F.; Giorgino, F.; Giorgino, R.; Cotecchia, S. Expression and secretion of the atrial natriuretic peptide in human adipose tissue and preadipocytes. Obesity (Silver Spring) 2007, 15, 2181-2189. [CrossRef]
  156. Kamberov, Y.G.; Karlsson, E.K.; Kamberova, G.L.; Lieberman, D.E.; Sabeti, P.C.; Morgan, B.A.; Tabin, C.J. A genetic basis of variation in eccrine sweat gland and hair follicle density. Proc Natl Acad Sci U S A 2015, 112, 9932-9937. [CrossRef]
  157. Best, A.; Kamilar, J.M. The evolution of eccrine sweat glands in human and nonhuman primates. J Hum Evol 2018, 117, 33-43. [CrossRef]
  158. Bramble, D.M.; Lieberman, D.E. Endurance running and the evolution of Homo. Nature 2004, 432, 345-352. [CrossRef]
  159. Hooper, J.D.; Clements, J.A.; Quigley, J.P.; Antalis, T.M. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem 2001, 276, 857-860. [CrossRef]
Preprints 74608 g001
Figure 1. Protein modules in selected TTSPs. All TTSPs contain an N-terminal transmembrane (TM) domain and a C-terminal trypsin-like protease domain. Protein modules between the transmembrane domain and the protease domain vary in individual TTSPs. HAT, human airway trypsin-like protease; SEA, sea urchin sperm protein, enteropeptidase, and agrin; SRCR, scavenger receptor cysteine-rich; MT2, matriptase-2; CUB, complement factor C1s/C1r, urchin embryonic growth factor, and bone morphogenetic protein; LDLR, low-density lipoprotein receptor; Fz, frizzled.
Figure 1. Protein modules in selected TTSPs. All TTSPs contain an N-terminal transmembrane (TM) domain and a C-terminal trypsin-like protease domain. Protein modules between the transmembrane domain and the protease domain vary in individual TTSPs. HAT, human airway trypsin-like protease; SEA, sea urchin sperm protein, enteropeptidase, and agrin; SRCR, scavenger receptor cysteine-rich; MT2, matriptase-2; CUB, complement factor C1s/C1r, urchin embryonic growth factor, and bone morphogenetic protein; LDLR, low-density lipoprotein receptor; Fz, frizzled.
Preprints 74608 g001
Preprints 74608 g002
Figure 2. A model of the hepsin/HGF/c-Met pathway in adipocytes. Hepsin activates HGF (hepatocyte growth factor), which in turn activates c-Met signaling and the downstream effectors including AKT (also known as protein kinase B). Subsequently, AKT inhibits PGC-1α, a transcriptional co-activator in adipocyte browning and mitochondrial gene expression.
Figure 2. A model of the hepsin/HGF/c-Met pathway in adipocytes. Hepsin activates HGF (hepatocyte growth factor), which in turn activates c-Met signaling and the downstream effectors including AKT (also known as protein kinase B). Subsequently, AKT inhibits PGC-1α, a transcriptional co-activator in adipocyte browning and mitochondrial gene expression.
Preprints 74608 g002
Preprints 74608 g003
Figure 3. Matriptase-2 function in hepcidin expression. In hepatocytes, bone morphogenetic protein (BMP) signaling enhances hepcidin expression. Matriptase-2 (MT2) sequesters and cleaves hemojuvelin (Hjv) and other BMP co-receptors on the cell surface, thereby downregulating BMP signaling and hepcidin expression. Matriptase-2 deficiency increases hepcidin levels in plasma, resulting in a protective phenotype against high-fat diet (HFD)-induced obesity and liver steatosis in mice.
Figure 3. Matriptase-2 function in hepcidin expression. In hepatocytes, bone morphogenetic protein (BMP) signaling enhances hepcidin expression. Matriptase-2 (MT2) sequesters and cleaves hemojuvelin (Hjv) and other BMP co-receptors on the cell surface, thereby downregulating BMP signaling and hepcidin expression. Matriptase-2 deficiency increases hepcidin levels in plasma, resulting in a protective phenotype against high-fat diet (HFD)-induced obesity and liver steatosis in mice.
Preprints 74608 g003
Preprints 74608 g004
Figure 4. A model of corin and ANP-mediated mechanisms in promoting lipolysis and browning in adipocytes. Corin activates ANP, which in turn binds to and activates its receptor, natriuretic peptide receptor A (NPR-A), thereby stimulating intracellular cGMP production. Increased cGMP levels promote lipolysis and adipocyte browning via the cGMP-dependent protein kinase I (cGKI)/hormone-sensitive lipase (HSL) pathway and the protein kinase G (PKG)/p38 mitogen-activated protein kinase (MAPK)/PGC-1α pathway, respectively.
Figure 4. A model of corin and ANP-mediated mechanisms in promoting lipolysis and browning in adipocytes. Corin activates ANP, which in turn binds to and activates its receptor, natriuretic peptide receptor A (NPR-A), thereby stimulating intracellular cGMP production. Increased cGMP levels promote lipolysis and adipocyte browning via the cGMP-dependent protein kinase I (cGKI)/hormone-sensitive lipase (HSL) pathway and the protein kinase G (PKG)/p38 mitogen-activated protein kinase (MAPK)/PGC-1α pathway, respectively.
Preprints 74608 g004
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated